Arundhati G Nair, Götz R A Ehrhardt, Eyal Grunebaum
{"title":"Variable Lymphocyte Receptor B Technologies - Are They Ready for Prime Time?","authors":"Arundhati G Nair, Götz R A Ehrhardt, Eyal Grunebaum","doi":"10.1080/08820139.2025.2462536","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To review the current and the potential research and clinical use of VLRBs.</p><p><strong>Methods: </strong>A literature search was conducted for English studies published in the past 20 years using the terms \"Variable Lymphocyte Receptor,\" \"VLR,\" \"VLRB\" or \"Repebody.\" Only primary reports were included.</p><p><strong>Results: </strong>VLRB-based technologies are currently being investigated for diagnosis, imaging, and treatment of diverse conditions including solid organ and hematological malignancies, infectious diseases, autoimmunity, and degenerative and metabolic disorders. VLRB mAbs can be used to directly recognize disease biomarkers, such as B cells from chronic lymphocytic leukemia, or to deliver drugs to the brain or cancer cells. The VLRB C-terminal multimerization domain has been utilized to create vaccines while VLR-based chimeric antigen receptor (CAR) T cell constructs are being investigated for cancer therapies.</p><p><strong>Conclusions: </strong>The extensive knowledge gained with VLRB mAbs in diverse <i>in vitro</i> and <i>in vivo</i> models emphasizes their promise for translation into clinical applications and readiness for prime time.</p>","PeriodicalId":13387,"journal":{"name":"Immunological Investigations","volume":" ","pages":"637-657"},"PeriodicalIF":2.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunological Investigations","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08820139.2025.2462536","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To review the current and the potential research and clinical use of VLRBs.
Methods: A literature search was conducted for English studies published in the past 20 years using the terms "Variable Lymphocyte Receptor," "VLR," "VLRB" or "Repebody." Only primary reports were included.
Results: VLRB-based technologies are currently being investigated for diagnosis, imaging, and treatment of diverse conditions including solid organ and hematological malignancies, infectious diseases, autoimmunity, and degenerative and metabolic disorders. VLRB mAbs can be used to directly recognize disease biomarkers, such as B cells from chronic lymphocytic leukemia, or to deliver drugs to the brain or cancer cells. The VLRB C-terminal multimerization domain has been utilized to create vaccines while VLR-based chimeric antigen receptor (CAR) T cell constructs are being investigated for cancer therapies.
Conclusions: The extensive knowledge gained with VLRB mAbs in diverse in vitro and in vivo models emphasizes their promise for translation into clinical applications and readiness for prime time.
期刊介绍:
Disseminating immunological developments on a worldwide basis, Immunological Investigations encompasses all facets of fundamental and applied immunology, including immunohematology and the study of allergies. This journal provides information presented in the form of original research articles and book reviews, giving a truly in-depth examination of the latest advances in molecular and cellular immunology.